TABLE 2.
Therapy regimens by treatment group
| Treatment typea | Total n = 132 (%) |
Cases n = 44 (%) | Controls n = 88 (%) |
|---|---|---|---|
| Empirical treatment | |||
| Monotherapy | 66/132 (50) | 18/44 (40.9) | 48/88 (54.5) |
| Ceftolozane-tazobactam | 4/66 (6) | 4/18 (22.2) | 0/48 (0) |
| Piperacilin/tazobactam | 23/66 (34.8) | 6/18 (33.3) | 17/48 (35.4) |
| Antipseudomonal carbapenems (meropenem/imipenem) | 28/66 (42.4) | 6/18 (33.3) | 22/48 (45.8) |
| Antipseudomonal cephalosporins (cefepime/ceftazidime) | 8/66 (12.1) | 2/18 (11.1) | 6/48 (12.5) |
| Othersb | 3/66 (4.5) | 0/18 (0) | 3/48 (6.2) |
| Combination therapy | 63/132 (47.3) | 23/44 (52.3) | 40/88 (45.5) |
| C/T + AG | 6/63 (9.5) | 6/23 (26.1) | 0/40 (0) |
| C/T + colistin | 1/63 (1.6) | 1/23 (4.3) | 0/40 (0) |
| Other β-lactam + AG | 42/63 (66.7) | 13/23 (56.5) | 30/40 (75) |
| Other β-lactam + non-AG | 9/63 (14.3) | 3/23 (13) | 6/40 (15) |
| Non-β-lactam combination | 4/63 (6.3) | 0/23 (0) | 4/40 (10) |
| No empirical treatment | 3/132 (2.3) | 3/44 (6.8) | 0/88 (0) |
| Targeted treatment | |||
| Monotherapy | 52/132 (39.4) | 17/44 (38.6) | 35/88 (39.8) |
| Ceftolozane-tazobactam | 16/52 (30.8) | 16/17 (94.1) | 0/35 (0) |
| Piperacilin/tazobactam | 8/52 (15.4) | 1/17 (5.9) | 9/35 (25.7) |
| Antipseudomonal carbapenems (meropenem, imipenem, doripenem) | 7/52 (13.5) | 3/17 (0) | 10/35 (28.5) |
| Colistin | 8/52 (15.4) | 0/17 (0) | 8/35 (22.9) |
| Antipseudomonal cephalosporins (cefepime, ceftazidime) | 3/52 (5.8) | 0/17 (0) | 3/35 (8.5) |
| Fluoroquinolones | 3/52 (5.8) | 0/17 (0) | 3/35 (8.6) |
| Amikacin | 2/52 (3.8) | 0/17 (0) | 2/35 (5.7) |
| Combination therapy (2 antibiotics) | 53/132 (40.2) | 21/44 (47.7) | 32/88 (36.4) |
| C/T + AG | 18/53 (30.1) | 14/21 (66.7) | 0/32 (0) |
| C/T + Colistin | 5/53 (9.4) | 5/21 (23.8) | 0/32 (0) |
| Other β-lactam + AG | 19/53 (35.8) | 1/21 (4.8) | 18/32 (56.2) |
| β-Lactam + non-AG | 8/53 (15.1) | 0/21 (0) | 8/32 (25) |
| Non-β-lactam combination | 7/53 (13.2) | 1/21 (4.8) | 6/32 (18.7) |
| Triple therapy | 16/132 (12.1) | 6/88 (6.8)c | 10/88 (11.4) |
| No treatment | 11/132 (8.3) | 0/44 (0) | 11/88 (12.5) |
a
CT, ceftolozane-tazobactam; AG, aminoglycoside.
b
Fluoroquinolone (n = 1), amikacin (n = 1), nonspecified antibiotic (n = 1).
c
Two patients received C/T in combination with colistin and fosfomycin.